8-K: Quantum-Si Reports Q2 2025 Results, Raises $50M

Quantum-Si Incorporated announced its second quarter 2025 financial results, reporting increased first-half revenue and a $50 million capital raise, despite experiencing commercial headwinds from NIH funding challenges.

Summary

• Second quarter 2025 revenue was $591,000.
• First half 2025 revenue reached $1.4 million, marking a 33% increase over the same period in 2024.
• Gross profit for Q2 2025 was $351,000, with a gross margin of 59%.
• Net loss for Q2 2025 increased to $28.8 million, compared to $23.1 million in Q2 2024.
• Adjusted EBITDA for Q2 2025 was negative $22.2 million, a slight improvement from negative $22.6 million in Q2 2024.
• A $50 million registered direct offering was completed on July 8, 2025, extending the cash runway into the second quarter of 2028.
• Cash and cash equivalents and investments in marketable securities totaled $214.2 million as of June 30, 2025.
• The ProteusTM platform development program remains on track for successful protein sequencing on a prototype by the end of 2025.
• The v4 Sequencing Kit is on track for a Q3 2025 launch, and the v3 Library Preparation Kit is on track for a Q4 2025 launch.
• Expanded instrument acquisition options were launched in response to current capital purchasing challenges.
• Two new R&D initiatives were announced to accelerate amino acid coverage and post-translational modifications (PTMs).

Sentiment

Score: 6

Explanation: While financial results show increased losses and a Q2 revenue decline, the significant capital raise, extended cash runway, and on-track product development initiatives provide a strong positive outlook for future execution and stability, balancing the near-term commercial headwinds.

Positives

• First half 2025 revenue increased 33% to $1.4 million compared to the same period in 2024.
• A $50 million registered direct offering was successfully completed, significantly strengthening the cash position.
• The cash runway has been extended into the second quarter of 2028, providing long-term financial stability.
• The ProteusTM platform development remains on track for successful protein sequencing on a prototype by the end of 2025.
• The Version 4 Sequencing Kit is on track for a Q3 2025 launch.
• The Version 3 Library Preparation Kit, expected to require significantly lower sample input, is on track for a Q4 2025 launch.
• Expanded instrument acquisition options were launched to address capital purchasing challenges and drive user base growth and consumable revenue.
• Two new R&D initiatives were announced to accelerate amino acid coverage and post-translational modifications (PTMs).
• Adjusted EBITDA improved slightly in Q2 2025 to negative $22.2 million from negative $22.6 million in Q2 2024.

Negatives

• Second quarter 2025 revenue of $591,000 was lower than the $622,000 reported in Q2 2024.
• Experienced the full effect of NIH funding challenges, which slowed and, in some cases, stopped the capital sales process.
• Net loss increased to $28.8 million in Q2 2025 from $23.1 million in Q2 2024.
• Total operating expenses increased to $30.5 million in Q2 2025 from $26.8 million in Q2 2024.
• Adjusted total operating expenses for the six months ended June 30, 2025, increased to $46.6 million from $46.3 million in the prior year period.
• Gross margin is expected to be variable in the near term due to initial commercialization stages and the timing and mix of product sales.

Risks

• Inability to maintain the listing of Class A common stock on The Nasdaq Stock Market.
• Ability to grow and manage growth profitably and retain key employees.
• Ongoing leadership transitions.
• Changes in applicable laws or regulations.
• Ability to raise financing in the future.
• Success, cost, and timing of product development and commercialization activities, including the use and benefit of artificial intelligence.
• Commercialization and adoption of existing products and the success of any product offered in the future.
• Potential attributes and benefits of commercialized Platinum protein sequencing instruments and kits and other products once commercialized.
• Ability to obtain and maintain regulatory approval for products, and any related restrictions and limitations of any approved product.
• Ability to identify, in-license or acquire additional technology.
• Ability to maintain existing lease, license, manufacture and supply agreements.
• Ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources.
• Size and growth potential of the markets for products and services, and ability to serve those markets once commercialized, either alone or in partnership with others.
• Estimates regarding future expenses, future revenue, capital requirements and needs for additional financing.
• Financial performance.

Future Outlook

The company expects to launch its v4 Sequencing Kit in Q3 2025 and its v3 Library Preparation Kit in Q4 2025. It remains on track to achieve successful protein sequencing on a prototype Proteus system by the end of 2025. The recent $50 million capital raise is expected to extend the cash runway into the second quarter of 2028. Management remains confident in the long-term market opportunity in proteomics and its technology roadmap.

Management Comments

• "We completed another productive quarter, in particular with our various product development initiatives, across platforms, Sequencing and Library Prep Kits as well as announcing the transition from technology development to product development for two new initiatives aimed at accelerating amino acid coverage and PTMs." Jeff Hawkins, President and Chief Executive Officer.
• "In the second quarter, we experienced the full effect of the NIH funding challenges which slowed and, in some cases, stopped the capital sales process." Jeff Hawkins, President and Chief Executive Officer.
• "Despite the capital spend slow down, we continue to engage with customers who have operating budgets they wish to deploy towards purchasing protein sequencing consumables for their research." Jeff Hawkins, President and Chief Executive Officer.
• "On the development front, our R&D team continues to execute well, and our version 4 Sequencing Kit remains on track for a Q3 2025 launch." Jeff Hawkins, President and Chief Executive Officer.
• "We expect to provide detailed updates to these program and other initiatives at an Investor & Analyst Day planned for mid-November 2025 in New York City." Jeff Hawkins, President and Chief Executive Officer.
• "While we experienced some near-term headwinds commercially this quarter, we continue to remain confident in the long-term market opportunity in proteomics and our technology roadmap we are executing against. We are laser focused on delivering on this roadmap and are well capitalized to execute." Jeff Hawkins, President and Chief Executive Officer.

Industry Context

The company operates in the proteomics technology sector, aiming to redefine protein analysis through single-molecule detection. The reported slowdown in capital sales due to NIH funding challenges indicates a broader impact on research and development spending within the life sciences industry, particularly affecting companies reliant on institutional capital expenditures. Quantum-Si's response, offering expanded instrument acquisition options, suggests an adaptation to current market conditions where operating budgets for consumables are more accessible than capital budgets for instruments. The focus on accelerating amino acid coverage and PTMs aligns with key areas of advancement in proteomics research.

Comparison to Industry Standards

• The strategy to offer expanded instrument acquisition options (e.g., placements for consumable purchases) is a common tactic in the life sciences instrument market, similar to models used by companies like Illumina (genomics) or Thermo Fisher Scientific (various lab instruments) to drive adoption and recurring revenue from consumables, especially when capital budgets are constrained.
• The reported 33% revenue increase for the first half of 2025, while positive, is on a relatively small base ($1.4 million), indicating the company is still in early commercialization stages. Larger, more established players in the broader life sciences tools market typically report much higher revenue figures and growth rates, though often from more mature product lines.
• The significant net losses and negative Adjusted EBITDA are typical for early-stage biotechnology companies heavily investing in R&D and commercialization, similar to many emerging companies in the genomics or cell therapy space that require substantial capital to bring novel technologies to market.
• The $50 million capital raise and extended cash runway into Q2 2028 are crucial for a company in this development stage, providing a longer financial lifeline compared to many smaller biotech firms that might face more frequent and dilutive capital needs.

Legal Proceedings

• Accrued legal settlement liability of $8.0 million as of June 30, 2025.
• Legal settlement insurance receivable of $4.638 million as of June 30, 2025.
• Legal settlement expense, net of insurance proceeds, of $3.362 million for Q2 and H1 2025.

Stakeholder Impact

• Shareholders: Experienced dilution from the $50 million registered direct offering, but gained increased financial stability and an extended cash runway. Potential for future value creation is tied to successful product development and commercialization.
• Customers: Benefit from expanded instrument acquisition options, providing more flexible purchasing models despite capital purchasing challenges. Anticipate enhanced capabilities and lower sample input requirements with upcoming v4 Sequencing Kit, v3 Library Prep Kit, and Proteus system.
• Employees: Continued funding for R&D and commercialization efforts supports ongoing operations and job stability.
• Creditors: Benefit from improved financial liquidity due to the recent capital raise.

Next Steps

• Launch of v4 Sequencing Kit in Q3 2025.
• Launch of v3 Library Preparation Kit in Q4 2025.
• Achieve successful protein sequencing on a prototype Proteus system by the end of 2025.
• Host an Investor & Analyst Day in New York City in mid-November 2025 to provide detailed updates on programs and initiatives.
• Continue to drive growth of user base and capture consumable revenue through expanded instrument acquisition options.
• Continue funding ongoing commercialization efforts and the Proteus development program.

Key Dates

Recommendation

While the company reported a decline in Q2 revenue and increased net losses, reflecting near-term commercial headwinds from NIH funding challenges, the successful $50 million capital raise significantly strengthens its balance sheet and extends its cash runway into Q2 2028. This provides crucial financial stability for continued R&D and commercialization efforts. Key product development milestones, including the Proteus platform, v4 Sequencing Kit, and v3 Library Preparation Kit, remain on track, indicating progress on the technology roadmap. The launch of flexible instrument acquisition options is a proactive step to address market challenges. Given the early stage of commercialization, the current financial performance is expected, but the extended cash runway mitigates immediate liquidity concerns. Investors should hold to monitor the execution of product launches, customer adoption rates, and the impact of the new acquisition models, as these will be critical for future revenue growth and profitability.

Keywords

Proteomics, Protein Sequencing, Biotechnology, Life Sciences, Research Tools, QSI, Quantum-Si, NIH Funding, Capital Raise, Nasdaq, Financial Results